STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
Kane PB, Benjamin DM, Barker RA, Lang AE, Sherer T, & Kimmelman J. Forecasts for the Attainment of Major Research Milestones in Parkinson’s Disease. Journal of Parkinson’s Disease, Apr 24, 2020.
London AJ, Kimmelman J. Against pandemic research exceptionalism. Science. April 23, 2020.
En kris är ingen ursäkt för sänkta krav på forskning, Dagens Nyheter, April 26, 2020.
Shortcuts in COVID-19 Drug Research Could Do Long-Term Harm, Bioethicists Worry, Scientific American, April 24, 2020.
Alertan de la baja calidad de numerosos estudios sobre el coronavirus. El Mundo. April 23, 2020.
Attention aux dérives de la recherche clinique, disent des chercheurs. Radio Canada. April 23, 2020.
La crise n'est pas une raison pour assouplir les normes scientifiques et éthiques, selon des experts. Le Devoir. April 23, 2020.
Zhang SX, Fergusson D, Kimmelman J. Proportion of Patients in Phase 1 Oncology Trials Receiving Treatments that are Ultimately Approved. Journal of the National Cancer Institute. April 1, 2020.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials, Cancer Therapy Advisor, May 13, 2020.
Carlisle BG, Doussau A, Kimmelman J. Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. BMJ Open. February 17, 2020.
Federico C, Mogil JS, Ramsay T, Fergusson DA, Kimmelman J. A systematic review and meta-analysis of pregabalin preclinical studies. Pain. January 22, 2020.
Hutchinson N, Vinarov E, Iasonos A, Kimmelman J. Ethical and Policy Issues for Seamless Phase I Oncology Trials. Journal of Clinical Oncology. December 26, 2019.
Feustel AC, MacPherson A, Fergusson DA, Kieburtz K, Kimmelman J. Risks and benefits of unapproved, disease-modifying treatments for neurodegenerative disease. Neurology. December 2, 2019.
Rezak M, de Carvalho M. Disease modification in neurodegenerative diseases: Not quite there yet. Neurology. December 2, 2019.
Sarvas H, Carlisle B, Dolter S, Vinarov E, Kimmelman J. Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. Journal of the National Cancer Institute. November 13, 2019.
Carlisle BG, Zheng T, Kimmelman J. Imatinib and the long tail of targeted drug development. Nature Reviews Clinical Oncology. October 24, 2019.
Doussau A, Vinarov E, Barsanti-Innes B, Kimmelman J. Comparison between protocols and publications for prognostic and predictive cancer biomarker studies. Clinical Trials. October 5, 2019.
Carlisle BG, Doussau A, Kimmelman J. Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials. October 3, 2019.
Kimmelman J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nature Reviews Clinical Oncology. August 30, 2019.
London AJ, Kimmelman J. Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. Hastings Center Report. August 20, 2019.
In Hunting for Cures, Ethics Can Strengthen Clinical Trials. Carnegie Mellon News. November 6, 2019.
MacPherson A, Kimmelman J. Ethical development of stem-cell-based interventions. Nature Medicine. July 3, 2019.
Jonathan Kimmelman quoted in STAT News on the ethical questions surrounding patient funding of clinical trials.
Cancer Therapy Advisor covers research published by Jonathan Kimmelman and student Sean Zhang on the proportion of patients in Phase 1 oncology trials that receive treatments that are ultimately approved.
Jonathan Kimmelman quoted in La Presse on the ethical issues with challenge studies for testing COVID-19 interventions.
Jonathan Kimmelman quoted in Wired on the costs of making treatment decisions based on preliminary findings.
Radio Canada, Scientific American, Le Devoir, El Mundo, Der Spiegel, Dagens Nyheter, and The Washington Post cover research published by Jonathan Kimmelman and collaborator Alex John London in Science on the scientific standards for pandemic research.
Jonathan Kimmelman quoted in Dallas News on the inconclusive evidence around experimental COVID-19 interventions.
Jonathan Kimmelman quoted in Clinical Research News on the distinction between research and care in the context of the WHO's malaria vaccine implementation programme.
Jonathan Kimmelman quoted in Vox on the ethical obligation to practice social distancing during the COVID-19 pandemic.
Jonathan Kimmelman quoted in STAT News on a first-in-human trial of an experimental COVID-19 vaccine without prior animal testing.
Jonathan Kimmelman quoted in BMJ on the ethics of the WHO's malaria vaccine study.
Jonathan Kimmelman quoted in Bloomberg on the selection of drugs and combinations for clinical testing in cancer patients.
Jonathan Kimmelman quoted in Nature on placebo-controlled clinical trials for regenerative medicine in an article on Japan's regulation of cell-based interventions.
Jonathan Kimmelman quoted in Neurology Today on the risks and benefits of Alzheimer's prevention trials.
Jonathan Kimmelman quoted in Nature on the use of registries for preclinical trials.
Jonathan Kimmelman quoted in Chemistry World on the hype surrounding unproven stem-cell based interventions.